New Treatment Alternatives in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma (NHL) – Update From American Society of Clinical Oncology (ASCO), Chicago 2013

Idelalisib (GS-1101) was the subject of multiple abstracts at ASCO.

The agent has activity when:

(1)  Abstract 7003 combined with rituxan (R) and or bendamustine (B) as first line therapy in indolent NHL – phase I

(2) Abstract 7005 combined with R as front line therapy in CLL or small lymphocytic lymphoma (SLL) – phase II

(3) Abstract 7017 single agent in relapsed or refractory chronic lymphocytic leukemia patients – phase III

(4) Abstract 7131 combined with ofatumumab for previously treated CLL – phase III

(5) Abstract 8579 signal pathway study

(6) Abstract 8526 single agent, relapsed or refractory NHL – phase I

(7) Abstract 8500 with R and/or B in patients prior treatment of indolent(i)NHL – phase I

(8) Abstract 7133 with B and R for previously treated CLL – phase III

(9) Abstract 8618 with B and R for previously treated iNHL – phase III

(10) Abstract 8519 single agent relapsed or refractory mantle cell lymphoma (MCL)

(11) Abstract 8501 combined with everolimus(S), bortezomin(B), or B/R in previously treated MCL

Comment: The most interesting studies were abstracts 8519 and 8501. It appears that Idelalisib is active in patients with previously treated MCL; however durability of response and toxicity when combined with other agents was significant. Time on study was extraordinarily brief particularly noteworthy in abstract 8501.

05 July 2013, 13:25
Add comment

Comments (0)